Live Analyst Rating Changes 36623 upgrades, downgrades & price-target moves · freshest Wall Street data, updated daily View live feed →
Analyst Tracker/James Quigley
GS

James Quigley

Goldman Sachs
Wall Street Analyst
★★☆☆☆
#2592
on 13Foresight · ranked by our own returns
43%
Success Rate
-1.9%
Average Return
19 of 44 calls profitable · -11.7% vs benchmark
S&P 500 (SPY)
📈 Across the calls we could measure, roughly 43% of James Quigley's ratings turned a profit when each position was held for 1 year — averaging -1.9% per rating. These figures are computed by 13Foresight from historical prices, not supplied by the analyst.

Rating Distribution

33 Buy 33 Hold 12 Sell
James's Stock Coverage 25 ratings · 2026-10-04
Company Date Position Consensus ⓘ Price Target ⓘ 1-Yr Return vs S&P 500 ⓘ
CH:LONN
Lonza Group Ltd
 Oct 01, 2026 BUY Strong Buy
+14.9% avg upside
21 analysts
$680.00
20.13% Upside
 +0.0% ·
FR:DIM
Sartorius Stedim Biotech
 Oct 01, 2026 BUY Strong Buy
+24.1% avg upside
12 analysts
$223.00
7.02% Upside
 +0.0% ·
DE:SRT3
Sartorius
 Oct 01, 2026 HOLD Strong Buy
+13.1% avg upside
19 analysts
$244.00
2.90% Downside
 +0.0% ·
CH:NOVN
Novartis AG
 Sep 30, 2026 SELL Buy
-4.0% avg upside
32 analysts
$110.00
5.49% Downside
 +1.5% ·
GB:0QIU
Novo Nordisk
 Sep 21, 2026 HOLD Hold
+63.2% avg upside
29 analysts
$285.00
14.58% Upside
 · ·
CH:ROP
Roche Holding AG
 Sep 15, 2026 HOLD Buy
-0.6% avg upside
24 analysts
$366.00
5.81% Upside
 -4.6% ·
NVO
Novo Nordisk
 Aug 06, 2026 HOLD Hold
+210.3% avg upside
26 analysts
$44.00
17.93% Upside
 -17.8% ·
DE:BAYN
Bayer
 Aug 05, 2026 BUY Strong Buy
+21.2% avg upside
31 analysts
$63.50
41.37% Upside
 -9.0% ·
FR:SAN
Sanofi
 Jul 06, 2026 HOLD Strong Buy
+37.6% avg upside
30 analysts
$84.00
18.58% Upside
 -6.6% ·
DE:MRK
Merck KGaA
 Apr 16, 2026 BUY Buy
+1.8% avg upside
34 analysts
$147.00
7.41% Upside
 +17.8% ·
RHHBY
Roche Holding
 Jan 15, 2026 HOLD Buy
+0.1% avg upside
14 analysts
 — -0.4% ·
NVS
Novartis
 Sep 12, 2025 SELL Buy
-1.1% avg upside
24 analysts
$118.00
16.36% Downside
 -13.9% ·
GB:BYG
Big Yellow Group
 Jul 30, 2025 HOLD Buy
+38.7% avg upside
13 analysts
 — -5.1% ·
SNY
Sanofi
 Jul 03, 2025 HOLD Strong Buy
+83.3% avg upside
20 analysts
$60.00
50.38% Upside
 -5.7% ·
GB:AZN
AstraZeneca
 May 30, 2024 BUY Strong Buy
+26.9% avg upside
28 analysts
$15200.00
28.12% Upside
 -12.0% ·
FR:EAPI
Euroapi SA
 Oct 10, 2023 HOLD Buy
+979.9% avg upside
5 analysts
$10.50
1320.86% Upside
 -40.0% ·
CH:PPGN
PolyPeptide Group AG
 Sep 25, 2023 HOLD Hold
-17.4% avg upside
3 analysts
$21.00
52.39% Downside
 +87.3% ·
CH:BANB
Bachem Holding AG
 Sep 25, 2023 SELL Sell
-4.3% avg upside
4 analysts
$64.00
19.21% Downside
 -7.6% ·
DE:EVT
Evotec
 Sep 25, 2023 BUY Buy
+469.0% avg upside
8 analysts
$28.00
858.93% Upside
 -67.3% ·
NL:LKFT
Lakefront Biotherapeutics NV
 Sep 05, 2023 HOLD Sell
+98.0% avg upside
17 analysts
$36.00
40.24% Upside
 -27.8% ·
EVO
Evotec AG
 Aug 08, 2023 BUY Buy
+421.8% avg upside
9 analysts
$15.00
837.47% Upside
 -75.5% ·
GB:0QW0
arGEN X
 Jul 28, 2023 BUY Strong Buy
-22.8% avg upside
25 analysts
$545.00
33.25% Downside
 +0.7% ·
GB:0MGB
Genmab A/S
 May 12, 2023 SELL Buy
-6.9% avg upside
25 analysts
$2235.00
1.08% Downside
 +31.2% ·
LKFT
Lakefront Biotherapeutics
 Jan 05, 2020 HOLD Buy
+249.3% avg upside
25 analysts
$205.00
597.89% Upside
 -51.9% ·
GMAB
Genmab
 Jun 20, 2018 BUY Strong Buy
+82.1% avg upside
27 analysts
 — +16.0% ·
🔒 20 more ratings — with price targets, crowd consensus and our measured returns.
Sign in free to unlock See Pro plans
Free account unlocks every analyst's full coverage table.
James Quigley — Frequently Asked Questions
How accurate are James Quigley's stock ratings?
Based on the calls 13Foresight could measure, about 43% of James's ratings were profitable over a one-year hold, with an average return of -1.9% per rating, or -11.7% versus the S&P 500. We score every analyst the same way, from historical prices. Each return is measured in the stock's own trading currency, so for non-US listings the S&P 500 comparison leaves out currency moves.
How is James ranked on 13Foresight?
James Quigley is currently ranked #2592 with a 2-star rating. Our rank blends hit rate, average return versus the market, and how many calls we have to judge — so a long, consistent record outweighs a few lucky picks. It is our own calculation, updated daily.
Which stocks does James cover?
James most recently has ratings on CH:LONN, FR:DIM, DE:SRT3, CH:NOVN, GB:0QIU, CH:ROP, NVO, DE:BAYN, FR:SAN, DE:MRK, RHHBY, NVS and 13 more. See the full coverage table above for positions, price targets and our measured returns.
Where can I see other analyst ratings?
Browse the full analyst leaderboard to compare Wall Street analysts ranked by their measured performance, success rate and average return.

Disclaimer: 13Foresight compiles analyst ratings and price targets from publicly available sources. Performance metrics, rankings and star ratings shown here are calculated independently by 13Foresight from historical market prices and may differ from figures published elsewhere. This information may be incomplete, delayed or inaccurate, is provided for research and informational purposes only, and is not investment advice. The underlying ratings and opinions are those of the respective analysts and their firms; 13Foresight accepts no liability for any decisions made based on this data.